The present invention relates to novel polymorphic forms of rosiglitazone base, as well as to a process for their preparation and pharmaceutical formulations containing it. The present polymorphic forms of rosiglitazone base are characterized by small average particle sizes and high solubility bestowing the compounds an improved bioavilability.
